Por Renan Filho · 2026-10-12**Lead**
A novel injectable therapy designed to shrink the dangerous fat that wraps around internal organs has achieved a 12% reduction in visceral adipose tissue in an early human trial, researchers announced this week. The treatment, administered as a series of injections directly into abdominal fat deposits, targets the metabolically active fat that is strongly linked to type 2 diabetes, cardiovascular disease, and non‑alcoholic fatty liver disease. While the trial involved only a small cohort of participants, the results mark a potential step toward a minimally invasive alternative to bariatric surgery or long‑term medication for visceral obesity.
**Context**
Visceral fat, unlike subcutaneous fat stored just under the skin, accumulates deep within the abdominal cavity around the liver, pancreas, and intestines. This type of fat is particularly harmful because it secretes inflammatory cytokines and free fatty acids that interfere with insulin signaling and promote chronic inflammation. Current interventions include lifestyle changes, GLP‑1 receptor agonists such as semaglutide, and surgical procedures like gastric bypass. However, many patients struggle to achieve or maintain significant reductions in visceral fat, and existing drugs often come with gastrointestinal side effects or require lifelong adherence.
The experimental injection, developed by a biotechnology firm based in the United States, uses a proprietary formulation of small molecules designed to induce localized lipolysis — the breakdown of fat cells — without affecting surrounding tissues. In preclinical animal models, the compound selectively targeted visceral adipocytes while sparing subcutaneous fat. The early human trial, which enrolled approximately 30 adults with class I or class II obesity, measured changes in visceral fat volume using MRI scans before and after a 12‑week treatment period. Participants received four injections spaced three weeks apart. The primary endpoint was the percentage reduction in visceral adipose tissue, which averaged 12% across the group. Secondary endpoints included improvements in waist circumference and fasting insulin levels, both of which showed modest but statistically significant changes.
**Analysis**
The 12% reduction, while modest compared to the 20–30% drops often seen with bariatric surgery, is notable because it was achieved with a localized, non‑systemic approach. If confirmed in larger and longer trials, the injection could offer a middle‑ground option for the millions of Americans who are overweight or obese but do not qualify for or wish to avoid surgery. The treatment also appears to avoid the nausea and vomiting commonly associated with GLP‑1 drugs, as the compound acts locally rather than on brain appetite centers.
However, experts caution that the trial’s small size and short duration leave many questions unanswered. It remains unclear whether the fat loss is sustained after the injections stop, whether the body compensates by regaining fat in other depots, and what the long‑term safety profile looks like. One concern is the potential for inflammation or fibrosis at the injection site, which was not reported in this early study but could emerge with repeated dosing. Additionally, the trial did not include a placebo group, making it difficult to rule out a placebo effect or the influence of concurrent lifestyle changes.
The broader significance lies in the growing recognition that not all fat is equal. Pharmaceutical companies have been racing to develop drugs that specifically target visceral fat, as it is a stronger predictor of metabolic disease than overall body mass index. This injection represents a novel delivery mechanism — direct administration into the fat depot — that could complement systemic therapies. If later‑stage trials confirm the efficacy and safety, the treatment could be positioned as an adjunct to diet and exercise, or as a bridge for patients awaiting surgery.
**Sources**
The information in this article is based on a press release issued by the biotechnology company conducting the trial, as well as a presentation of preliminary data at the annual meeting of the American Association of Clinical Endocrinology. Additional context was drawn from published literature on visceral adipose tissue and obesity treatments in peer‑reviewed journals such as *Nature Reviews Endocrinology* and *The New England Journal of Medicine*. No independent verification of the data has been performed by FORTIS NEWS.